Bupropion in the treatment of major depressive disorder: A comparison with paroxetine;Bupropione nel trattamento del disturbo depressivo maggiore: Confronto con paroxetina

Italian Journal of Psychopathology

Volumn 16, Issue 1, 2010, Pages 128-133

  Calandra, C ^a   Terranova, F ^a   Loiacono, P ^a   Caudullo, V ^a   Russo, R G ^a   Luca, M ^a   Cafiso, M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PAROXETINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL HEALTH CENTER; MONTGOMERY ASBERG DEPRESSION RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

EID: 77952976019     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCI: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005;7:106-113
2. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine re-uptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159-166
3. Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am J Ther 2007;14:241-246
4. Gross PK, Nourse R, Wasser TE, Bukenya D. Safety and efficacy of bupropion extended-release in treating a community sample of Hispanic and African American adults with major depressive disorder: An open-label study. Prim Care Companion J Clin Psychiatry 2007;9:108-112
5. Tomarken AJ, Dichter GS, Freid C, Addington S, Shelton RC. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord 2004;78:235-241
6. Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: finding from a, randomized, double-blind placebo-controlled study. J Clin Psychiatry 2006;67:865-873
7. Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG. Effect of bupropion SR on specific symptom clusters of depression: analysis on the 31-item Hamilton Rating Scale for Depression. Psychopharmacol Bull 2003;37:67-78.
8. Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, Goodale EP, et al. Efficacy of bupropion and the SSRIs in the treatment of anxiety symptoms in MDD: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 2008;42:134-140
9. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, et al. Efficacy of bupropion and the SSRIs in the treatment of MDD with high levels of anxiety (anxious depression): A pooled analysis of 10 studies. J Clin Psychiatry 2008;69:1287-1292
10. Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001;62:776-781
11. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;(2):CD006117.
12. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, Lohr KN. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008;31:851-865
13. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001;35:1608-1613
14. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion SR and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532-537
15. Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, et al. Remission rates following antidepressants therapy with bupropion or SSRIs: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974-978
16. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
17. Kinzl JF. Major depressive disorder, antidepressants and sexual dysfunction. Neuropsychiatr 2009;23:134-138
18. Kennedy SH, Fulton KA, Bagby RM, Greene AL, Cohen NL, Rafi-Tari S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;51:234-242
19. Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry 2007;68:1907-1912
20. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of steepness and fatigue in major depressive disorder: a comparison of bupropion and the SSRIs. Biol Psychiatry 2006;60:1350-1355
21. Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. Ann Intern Med 2000;132:738-742
22. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-733
23. Demyttenaere K, Jaspers L. Review: bupropion and SSRI-induced side effects. J Psychopharmacol 2008;22:792-804.